Literature DB >> 8623562

The economic impact of failures in total hip replacement surgery: 28,997 cases from the Norwegian Arthroplasty Register, 1987-1993.

A Furnes1, S A Lie, L I Havelin, L B Engesaeter, S E Vollset.   

Abstract

The Norwegian Arthroplasty Register was established in 1987. Until January 1994, approximately 200 different implant combinations had been used in total hip replacements (THR) in Norway. About 5,500 THR were performed each year in this period with a total cost of 70 million USD per year. We analyzed the economic consequences related to the use of some inferior primary hip arthroplasties in this period. As the reference arthroplasty, we chose the most commonly used prosthesis in Norway, i.e., the Charnley prosthesis fixed with high viscosity cement containing antibiotic and with systemic antibiotic prophylaxis (n 4,970). We compared this reference group to all other primary THR registered in the same time period (n 24,027), and to the following sub-groups of primary THR: 1) uncemented Ti-Fit/ Bio-Fit (acetabulum/femur) combination (n 173), 2) uncemented Coxa/Femora combination (n 153), 3) THR with low-viscosity cement (n 1,807) and 4) THR with Boneloc cement (n 1,250). We estimated the number of additional revisions compared to the reference arthroplasty after a follow-up of 3-5 years in the different groups, with adjustment for age, sex and diagnosis. The direct extra revision costs were calculated. Compared to the reference arthroplasty, the group of all other primary THR gave an extra revision cost estimated at about 1.7 million USD per year. About 1,000 uncemented Bio-Fit femoral prostheses have been applied in Norway, including those implanted before the registration started (1985-1987). The extra revision costs the first postoperative years for these 1,000 prostheses amount to about 0.7 million USD per year. Corresponding figures in the Coxa/ Femora group were 0.08 million USD, in the group with low-viscosity cement, 0.3 million USD and in the Boneloc group, 0.4 million USD per year.

Entities:  

Mesh:

Year:  1996        PMID: 8623562     DOI: 10.3109/17453679608994653

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  7 in total

1.  Organisation, data evaluation, interpretation and effect of arthroplasty register data on the outcome in terms of revision rate in total hip arthroplasty.

Authors:  Gerold Labek; Wolfgang Janda; Mark Agreiter; Reinhard Schuh; Nikolaus Böhler
Journal:  Int Orthop       Date:  2010-10-05       Impact factor: 3.075

2.  First hip arthroplasty register in Italy: 55,000 cases and 7 year follow-up.

Authors:  S Stea; B Bordini; M De Clerico; K Petropulacos; A Toni
Journal:  Int Orthop       Date:  2007-11-07       Impact factor: 3.075

3.  What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Thomas J Parisi; Joseph F Konopka; Hany S Bedair
Journal:  Clin Orthop Relat Res       Date:  2017-04-07       Impact factor: 4.176

Review 4.  The incidence of implant fractures after total hip arthroplasty.

Authors:  Patrick Sadoghi; Wolfram Pawelka; Michael C Liebensteiner; Alexandra Williams; Andreas Leithner; Gerold Labek
Journal:  Int Orthop       Date:  2014-01       Impact factor: 3.075

5.  Fixation of hydroxyapatite-coated revision implants is improved by the surgical technique of cracking the sclerotic bone rim.

Authors:  Brian Elmengaard; Joan E Bechtold; Xinqian Chen; Kjeld Søballe
Journal:  J Orthop Res       Date:  2009-08       Impact factor: 3.494

6.  Unicompartmental knee resurfacing: enlarged tibio-femoral contact area and reduced contact stress using novel patient-derived geometries.

Authors:  Nick Steklov; John Slamin; Sudesh Srivastav; Darryl D'Lima
Journal:  Open Biomed Eng J       Date:  2010-03-12

7.  Finite Element Study on the Preservation of Normal Knee Kinematics with Respect to the Prosthetic Design in Patient-Specific Medial Unicompartmental Knee Arthroplasty.

Authors:  Yong-Gon Koh; Kyoung-Mi Park; Kyoung-Tak Kang
Journal:  Biomed Res Int       Date:  2020-03-18       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.